title: Does platelet mass influence the effectiveness of ibuprofen treatment for patent ductus arteriosus in preterm infants?
abstract: OBJECTIVE
  The aim of this study is to evaluate whether the platelet mass in the first 24 h of life is effective on closure of patent ductus arteriosus (PDA) or not.
  
  
  METHODS
  Preterm infants with a gestational age of < 32 weeks, hospitalized at a tertiary neonatal intensive care unit (NICU) and requiring medical treatment (intravenous or oral ibuprofen) for hemodinamically significant PDA (hsPDA) were enrolled in this study. The patients were divided into two groups after first course of pharmacologic treatment according to closure of PDA (Group 1: PDA closure, Group 2: PDA without closure). Groups were compared in terms of demographics findings, morbidities, platelet measurements like counts, mean platelet volume (MPV) and platelet mass (platelet count × mean platelet volume).
  
  
  RESULTS
  The study included 77 preterm newborns in Group 1, and 30 preterms in Group 2. There were no differences in birth weight, gestational age, gender and maternal risk factors between the study groups. The mean platelet count in the first postnatal blood count was in Group 1: 211.3 ± 89.2 × 10(3)/mm(3) and in Group 2: 216.5 ± 26 × 10(3)/mm(3), respectively (p = 0.783). The mean platelet volumes (MPV) were similar in both groups (p = 0.535). No statistically significant difference between platelet mass values was detected (Group 1: 1811 ± 884 fl/nl, Group 2: 1868 ± 717 fl/nl) (p = 0.753).
  
  
  CONCLUSIONS
  Our data suggest that platelet count, MPV and platelet mass did not affect the closure of hsPDA with ibuprofen.
authors.affiliation: a Department of Neonatology , and.
authors.forename: Selahattin
authors.initials: S
authors.lastname: Akar
authors.affiliation: a Department of Neonatology , and.
authors.forename: Nilgun
authors.initials: N
authors.lastname: Karadag
authors.affiliation: a Department of Neonatology , and.
authors.forename: Tulin
authors.initials: T
authors.lastname: Gokmen Yildirim
authors.affiliation: a Department of Neonatology , and.
authors.forename: Handan Hakyemez
authors.initials: HH
authors.lastname: Toptan
authors.affiliation: a Department of Neonatology , and.
authors.forename: Emre
authors.initials: E
authors.lastname: Dincer
authors.affiliation: a Department of Neonatology , and.
authors.forename: Abdulhamit
authors.initials: A
authors.lastname: Tuten
authors.affiliation: b Department of Pediatrics , Zeynep Kamil Maternity and Children Research and Training Hospital , İstanbul , Turkey.
authors.forename: Taner
authors.initials: T
authors.lastname: Yavuz
authors.affiliation: a Department of Neonatology , and.
authors.forename: Sevilay
authors.initials: S
authors.lastname: Topcuoglu
authors.affiliation: a Department of Neonatology , and.
authors.forename: Hande Ozgun
authors.initials: HO
authors.lastname: Karatepe
authors.affiliation: a Department of Neonatology , and.
authors.forename: Elif
authors.initials: E
authors.lastname: Ozalkaya
authors.affiliation: a Department of Neonatology , and.
authors.forename: Guner
authors.initials: G
authors.lastname: Karatekin
authors.affiliation: a Department of Neonatology , and.
authors.forename: Fahri
authors.initials: F
authors.lastname: Ovali
mesh_terms: D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004374:Ductus Arteriosus, Patent / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use*; D007231:Infant, Newborn; D007234:Infant, Premature / Q000097:blood*; D008297:Male; D063847:Mean Platelet Volume; D010976:Platelet Count; D011897:Random Allocation; D012189:Retrospective Studies; D018709:Statistics, Nonparametric
chemical_list: D016861:Cyclooxygenase Inhibitors; D007052:Ibuprofen
keywords: Patent ductus arteriosus; platelet mass; prematurity